The era of disease modifying therapy for Multiple Sclerosis (MS), which began with ACTH in the 1950s, has truly accelerated in the past 2 decades. Neuro-ophthalmologists should be aware of the important recent therapeutic advances that will impact their patients with MS.
Relation is Part of
NANOS Annual Meeting 2019: New Information I Should Know
Sashank Prasad, MD
Spencer S. Eccles Health Sciences Library, University of Utah